MediPharm Labs Statistics
Total Valuation
MediPharm Labs has a market cap or net worth of 26.96 million. The enterprise value is 18.67 million.
| Market Cap | 26.96M |
| Enterprise Value | 18.67M |
Important Dates
The next estimated earnings date is Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +12.30% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 387.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.92 |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.51 |
| EV / Sales | 0.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.36 |
Financial Position
The company has a current ratio of 3.15, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.15 |
| Quick Ratio | 1.85 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | -15.21 |
Financial Efficiency
Return on equity (ROE) is -22.24% and return on invested capital (ROIC) is -11.08%.
| Return on Equity (ROE) | -22.24% |
| Return on Assets (ROA) | -9.31% |
| Return on Invested Capital (ROIC) | -11.08% |
| Return on Capital Employed (ROCE) | -20.27% |
| Revenue Per Employee | 181,137 |
| Profits Per Employee | -46,164 |
| Employee Count | 161 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 3.08 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.16% in the last 52 weeks. The beta is 0.56, so MediPharm Labs's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +1.16% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 49.92 |
| Average Volume (20 Days) | 108,409 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MediPharm Labs had revenue of 29.16 million and -7.43 million in losses. Loss per share was -0.02.
| Revenue | 29.16M |
| Gross Profit | 9.41M |
| Operating Income | -6.09M |
| Pretax Income | -7.43M |
| Net Income | -7.43M |
| EBITDA | -4.33M |
| EBIT | -6.09M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 8.25 million in cash and 269,662 in debt, giving a net cash position of 7.98 million.
| Cash & Cash Equivalents | 8.25M |
| Total Debt | 269,662 |
| Net Cash | 7.98M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 30.01M |
| Book Value Per Share | 0.07 |
| Working Capital | 15.70M |
Cash Flow
In the last 12 months, operating cash flow was -3.38 million and capital expenditures -107,031, giving a free cash flow of -3.49 million.
| Operating Cash Flow | -3.38M |
| Capital Expenditures | -107,031 |
| Free Cash Flow | -3.49M |
| FCF Per Share | n/a |
Margins
Gross margin is 32.26%, with operating and profit margins of -20.88% and -25.49%.
| Gross Margin | 32.26% |
| Operating Margin | -20.88% |
| Pretax Margin | -25.49% |
| Profit Margin | -25.49% |
| EBITDA Margin | -14.84% |
| EBIT Margin | -20.88% |
| FCF Margin | n/a |
Dividends & Yields
MediPharm Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.30% |
| Shareholder Yield | -12.30% |
| Earnings Yield | -27.57% |
| FCF Yield | -12.93% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediPharm Labs has an Altman Z-Score of -2.48. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.48 |
| Piotroski F-Score | n/a |